Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

(2013) Yingmiao Liu et al.   Cancer Medicine

A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer

(2012) A. A. Secord et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

(2011) Christina I. Herold et al.   CLINICAL CANCER RESEARCH

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

(2011) Manish R. Sharma et al.   INVESTIGATIONAL NEW DRUGS

Current Status of Src Inhibitors in Solid Tumor Malignancies

(2011) L. N. Puls et al.   ONCOLOGIST

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

(2010) Eric B. Haura et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Faye M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress

(2009) S. Kopetz et al.   CANCER RESEARCH

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin

(2009) P. Ceppi et al.   MOLECULAR CANCER THERAPEUTICS

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells

(2008) Fei Fei et al.   BRITISH JOURNAL OF HAEMATOLOGY

Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis

(2008) M. P. Kim et al.   CELL AND TISSUE RESEARCH

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

(2008) Howard S. Hochster et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling

(2008) I Ischenko et al.   ONCOGENE